Slide 1: Simulations Plus Third Quarter FY 2011 Conference Call and Webinar
Simulations Plus, Inc. (NASDAQ:SLP) Third Quarter FY 2011 Conference Call and Webinar July 14, 2011
Slide 2: Safe Harbor Statement
With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause or contribute to such
Slide 3: SLP 3Q11 Highlights
• 3Q11 compared to 3Q10: – 15 th consecutive profitable quarter (37 of last 39 were profitable) – 3Q11 sales up 10.3% to record $3.44 million from $3.12 million – Pharmaceutical segment sales up 13.5% – Words+ subsidiary sales up 0.7% – Net Income up 42.4% to $1.054 million from $0.740 million – Dil
Slide 4: $28 $2.4 $2.1$2.1 or = 2008" 2009 a3 20102011 simulations pi:
$28 $2.4 $2.1$2.1 or = 2008" 2009 a3 20102011 simulations pi:
Slide 5: Quarterly Revenues Annual Revenues
Quarterly Revenues Annual Revenues asrprsegosraryrse sr rsesesese,, = Pharmaceutical" Words+ 2008 2007-2008 20082010 ‘Pharmaceutical Words+ simulations plus, inc. é
Slide 6: 2. ss $2.0 $2.0) $ $1414 $23] $13 $1151.41 “4 $18 $1 Q: =
2. ss $2.0 $2.0) $ $1414 $23] $13 $1151.41 “4 $18 $1 Q: = 2008 @ 2010 at 2 = 2009 3 ford = 2011 simulationsplus, inc, ¢
Slide 7: Gross Margin (consolidated)
Gross Margin (consolidated) 75.6% 78.9% 78.8% 70.4% 73.8% 74.4% 80.0% 67.9% 75.0% 76.3% 77.6% 75.6% 73.6% 77.6% 76.3%
Slide 8: a2 a3 a4
a2 a3 a4 = 2008" 2009" 2010" 2011 simulations plus, inc. é
Slide 9: Net Income
Net Income $243K $565K $764K $165K $312K $368K $569K $163K $430K $641K $740K $345K $567K $907K $1.054 M
Slide 10: Consolidated Income Statement
3Q11 3Q10 Pharmaceutical software and services revenue 2.640 2.325 Words+ revenue 0.799 0.794 Consolidated revenue 3.439 3.119 Gross profit 2.623 2.420 Gross profit margin 76.3% 77.6% SG&A 1.063 1.118 R&D 0.238 0.234 Total operating expenses 1.302 1.352 Income before income taxes 1.378 1.112 Net inc
Slide 11: Select Balance Sheet Items
May 31, 2011 May 31, 2010 Cash and cash equivalents $9.894 $8.583 Total current assets 13.771 12.335 Total assets $16.337 $14.566 Total current liabilities 1.747 1.342 Total liabilities 2.529 1.775 Shareholders’ equity 13.808 12.791 Total liabilities and shareholders’ equity 16.337 14.566 Select Bal
Slide 12: Marketing and Sales Program
Marketing and Sales Program • Fundamental industry shift continues – Pharma increasingly utilizing simulation software and modeling tools to increase productivity - steady stream of scientific meetings – Software tools are always evolving, and as the technology advances, new capabilities attract new
Slide 13: Simulations Plus continues to increase its technological advantage
• Simulations Plus continues to increase its technological advantage Ongoing Enhancements • Version 7.0 was released in August 2010 - a major upgrade • Three new market-expanding capabilities plus numerous features: • Drug-to-drug interaction (released, now in beta test for further expansions) • Ocu
Slide 14: Summary
Summary • For the trailing 12 months through May 31: - Revenues = $11.8 million (up 14.1%) - Net Income = $2.87 million (up 45.6% ) - Earnings/share = $0.18 (up 45.6% ) • Simulations Plus is globally recognized as a leader in our respective market niches - Outstanding reputation for scientific exper
Slide 15: simulations plus, inc. é
simulations plus, inc. é